LDLR and familial hyperaldosteronism: Recently, a study in a FH mouse model with a non-viral vector expressing LDLR cDNA combined with a microRNA which suppresses the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) has also led to a 32% lipid reduction, with a 40% atherosclerotic regression in vivo after 12 weeks of treatment (Kerr et al., 2016).